{"transactions":[{"id":856443,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":500,"price":326.08,"value":163040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":18693,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856442,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":510,"price":324.59,"value":165540.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":19193,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856441,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":740,"price":323.55,"value":239427.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":19703,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856440,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":654,"price":322.33,"value":210803.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20443,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856439,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":208,"price":325.67,"value":67739.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21097,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856438,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":272,"price":324.88,"value":88367.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21305,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856437,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":767,"price":323.84,"value":248385.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21577,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856436,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":350,"price":323.01,"value":113053.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22344,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856435,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":289,"price":321.82,"value":93005.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22694,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856434,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":215,"price":320.81,"value":68974.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22983,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856433,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":102,"price":320.01,"value":32641.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23198,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":856432,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-06T21:13:37.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":106,"price":319.03,"value":33817.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23300,"source":{"system":"sec-edgar","filing":"0001735276-26-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000063/edgardoc.xml","form_type":"4"}},{"id":862474,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Stock Option  (right to buy)","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"grant","planned":true,"acquired":true,"shares":10480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":10480,"derivative":{"exercise_price":325.07,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":10480},"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862473,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":463,"price":321.5,"value":148854.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.30 to $321.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23406,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862472,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":640,"price":320.48,"value":205107.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.97 to $320.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23869,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862471,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":317,"price":319.06,"value":101142.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.71 to $319.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24509,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862470,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":355,"price":316.74,"value":112442.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.45 to $317.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24826,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862469,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":42,"price":332.64,"value":13970.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25181,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862468,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":101,"price":331.93,"value":33524.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25223,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862467,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":87,"price":330.85,"value":28783.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25324,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862466,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":182,"price":329.71,"value":60007.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25411,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862465,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":107,"price":328.71,"value":35171.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25593,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862464,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":353,"price":327.67,"value":115667.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25700,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862463,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":421,"price":326.81,"value":137587.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26053,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862462,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":277,"price":325.63,"value":90199.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26474,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862461,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":97,"price":324.65,"value":31491.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26751,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862460,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":50,"price":323.62,"value":16181.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26848,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":862459,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:07.000Z","date":"2026-03-02","kind":"grant","planned":true,"acquired":true,"shares":4769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":26898,"source":{"system":"sec-edgar","filing":"0001735276-26-000052","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000052/edgardoc.xml","form_type":"4"}},{"id":874869,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Restricted Stock Units","published_at":"2026-03-02T21:08:43.000Z","date":"2026-02-27","kind":"exercise","planned":true,"acquired":false,"shares":1908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date.  On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1908},"source":{"system":"sec-edgar","filing":"0001735276-26-000038","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000038/edgardoc.xml","form_type":"4"}},{"id":874868,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-02T21:08:43.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":140,"price":334.39,"value":46814.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."}],"balance_after":22129,"source":{"system":"sec-edgar","filing":"0001735276-26-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000038/edgardoc.xml","form_type":"4"}},{"id":874867,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-02T21:08:43.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":942,"price":332.48,"value":313196.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.11 to $333.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22269,"source":{"system":"sec-edgar","filing":"0001735276-26-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000038/edgardoc.xml","form_type":"4"}},{"id":874866,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-02T21:08:43.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":1159,"price":331.49,"value":384196.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.09 to $332.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23211,"source":{"system":"sec-edgar","filing":"0001735276-26-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000038/edgardoc.xml","form_type":"4"}},{"id":874865,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-02T21:08:43.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":2259,"price":330.73,"value":747119.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.08 to $331.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24370,"source":{"system":"sec-edgar","filing":"0001735276-26-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000038/edgardoc.xml","form_type":"4"}},{"id":874864,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-02T21:08:43.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":127,"price":328.92,"value":41772.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.90 to $329.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26629,"source":{"system":"sec-edgar","filing":"0001735276-26-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000038/edgardoc.xml","form_type":"4"}},{"id":874863,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-03-02T21:08:43.000Z","date":"2026-02-27","kind":"exercise","planned":true,"acquired":true,"shares":1908,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":26756,"source":{"system":"sec-edgar","filing":"0001735276-26-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000038/edgardoc.xml","form_type":"4"}},{"id":901562,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-02-18T00:28:48.000Z","date":"2026-02-13","kind":"sale","planned":false,"acquired":false,"shares":2242,"price":310.0808,"value":695201.1536,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $302.55 to $314.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24848,"source":{"system":"sec-edgar","filing":"0001735276-26-000029","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000029/edgardoc.xml","form_type":"4"}},{"id":901561,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-02-18T00:28:48.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":4579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting the achievement of non-GAAP operating income for fiscal year 2025 on February 12, 2026, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors."}],"balance_after":27090,"source":{"system":"sec-edgar","filing":"0001735276-26-000029","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000029/edgardoc.xml","form_type":"4"}},{"id":939480,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":15,"price":377.82,"value":5667.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."}],"balance_after":22511,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939479,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":19,"price":375.65,"value":7137.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."}],"balance_after":22526,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939478,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":14,"price":374.44,"value":5242.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22545,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939477,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":3,"price":372.46,"value":1117.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22559,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939476,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":18,"price":370.87,"value":6675.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22562,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939475,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":40,"price":369.48,"value":14779.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22580,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939474,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":92,"price":368.62,"value":33913.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22620,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939473,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":41,"price":367.4,"value":15063.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22712,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939472,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":50,"price":366.41,"value":18320.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22753,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939471,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":220,"price":365.56,"value":80423.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22803,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939470,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":199,"price":364.83,"value":72601.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23023,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939469,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":47,"price":363.55,"value":17086.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23222,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939468,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":73,"price":362.38,"value":26453.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23269,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939467,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":98,"price":361.45,"value":35422.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23342,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939466,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":155,"price":360.22,"value":55834.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23440,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939465,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":85,"price":359.14,"value":30526.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23595,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939464,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":123,"price":358.18,"value":44056.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23680,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939463,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":96,"price":357.17,"value":34288.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23803,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939462,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":41,"price":356.09,"value":14599.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23899,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939461,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":42,"price":355.16,"value":14916.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23940,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939460,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":39,"price":353.95,"value":13804.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23982,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":939459,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:23:29.000Z","date":"2026-01-11","kind":"grant","planned":false,"acquired":true,"shares":3800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026."}],"balance_after":24021,"source":{"system":"sec-edgar","filing":"0001735276-26-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000015/edgardoc.xml","form_type":"4"}},{"id":1025135,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":215,"price":454.37,"value":97689.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F14","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.25 to $454.76. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20221,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025134,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":417,"price":453.51,"value":189113.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F14","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.94 to $453.75. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20436,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025133,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":898,"price":451.76,"value":405680.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F14","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.50 to $452.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20853,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025132,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":810,"price":450.63,"value":365010.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F14","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.47 to $451.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21751,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025131,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":682,"price":449.99,"value":306893.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F14","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.37 to $450.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22561,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025130,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":3,"price":457.64,"value":1372.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."}],"balance_after":23243,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025129,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":147,"price":457.43,"value":67242.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."}],"balance_after":23246,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025128,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":73,"price":455.82,"value":33274.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.42 to $456.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23393,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025127,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":244,"price":454.84,"value":110980.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23466,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025126,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":329,"price":453.77,"value":149290.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23710,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025125,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":668,"price":452.69,"value":302396.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24039,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025124,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":332,"price":451.86,"value":150017.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24707,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025123,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":541,"price":450.81,"value":243888.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25039,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025122,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":249,"price":449.79,"value":111997.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25580,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025121,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":180,"price":448.77,"value":80778.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25829,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025120,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":56,"price":447.92,"value":25083.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26009,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025119,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":115,"price":446.53,"value":51350.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26065,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025118,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-01","kind":"grant","planned":true,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 1, 2024, the reporting person was granted a PSU under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the PC&C Committee on October 1, 2025."}],"balance_after":26180,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1025117,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-10-03T21:12:26.000Z","date":"2025-10-01","kind":"grant","planned":true,"acquired":true,"shares":3108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study of an RNAi therapeutic in development to treat a prevalent disease, as determined by the People, Culture and Compensation (PC&C) Committee of the Issuer Board of Directors on October 1, 2025."}],"balance_after":23329,"source":{"system":"sec-edgar","filing":"0001735276-25-000113","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000113/edgardoc.xml","form_type":"4"}},{"id":1062601,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-19","kind":"sale","planned":true,"acquired":false,"shares":45,"price":461.74,"value":20778.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024."}],"balance_after":20221,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062600,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-19","kind":"sale","planned":true,"acquired":false,"shares":305,"price":461.01,"value":140608.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $460.60 to $461.44. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20266,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062599,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-19","kind":"sale","planned":true,"acquired":false,"shares":260,"price":459.59,"value":119493.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $459.20 to $460.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20571,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062598,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-19","kind":"sale","planned":true,"acquired":false,"shares":231,"price":458.27,"value":105860.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $457.76 to $458.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20831,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062597,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-19","kind":"sale","planned":true,"acquired":false,"shares":338,"price":457.26,"value":154553.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $456.64 to $457.51. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21062,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062596,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-19","kind":"sale","planned":true,"acquired":false,"shares":276,"price":455.41,"value":125693.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.94 to $455.77. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21400,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062595,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":12,"price":455.82,"value":5469.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21676,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062594,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":241,"price":454.84,"value":109616.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21688,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062593,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":543,"price":454.04,"value":246543.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21929,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062592,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":329,"price":452.96,"value":149023.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22472,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062591,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":103,"price":451.99,"value":46554.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22801,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062590,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":39,"price":450.92,"value":17585.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22904,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062589,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":90,"price":449.92,"value":40492.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22943,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062588,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":39,"price":447.98,"value":17471.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23033,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1062587,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief R&D"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:53.000Z","date":"2025-08-15","kind":"grant","planned":true,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025."}],"balance_after":23072,"source":{"system":"sec-edgar","filing":"0001735276-25-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000092/edgardoc.xml","form_type":"4"}},{"id":1192485,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & EVP Dev & Med Affairs"}}],"security":"Stock Option  (right to buy)","published_at":"2025-03-25T20:10:23.000Z","date":"2025-03-24","kind":"exercise","planned":true,"acquired":false,"shares":5445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option was fully vested and exercisable as of December 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":42.22,"expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":5445},"source":{"system":"sec-edgar","filing":"0001735276-25-000041","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000041/edgardoc.xml","form_type":"4"}},{"id":1192484,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & EVP Dev & Med Affairs"}}],"security":"Common Stock","published_at":"2025-03-25T20:10:23.000Z","date":"2025-03-24","kind":"sale","planned":true,"acquired":false,"shares":5445,"price":300,"value":1633500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024."}],"balance_after":20221,"source":{"system":"sec-edgar","filing":"0001735276-25-000041","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000041/edgardoc.xml","form_type":"4"}},{"id":1192483,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & EVP Dev & Med Affairs"}}],"security":"Common Stock","published_at":"2025-03-25T20:10:23.000Z","date":"2025-03-24","kind":"exercise","planned":true,"acquired":true,"shares":5445,"price":42.22,"value":229887.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024."}],"balance_after":25666,"source":{"system":"sec-edgar","filing":"0001735276-25-000041","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000041/edgardoc.xml","form_type":"4"}},{"id":1192482,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & EVP Dev & Med Affairs"}}],"security":"Common Stock","published_at":"2025-03-25T20:10:23.000Z","date":"2025-03-21","kind":"sale","planned":true,"acquired":false,"shares":4321,"price":285,"value":1231485.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024."}],"balance_after":20221,"source":{"system":"sec-edgar","filing":"0001735276-25-000041","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000041/edgardoc.xml","form_type":"4"}},{"id":1223340,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & EVP Dev & Med Affairs"}}],"security":"Stock Option  (right to buy)","published_at":"2025-03-05T21:21:52.000Z","date":"2025-03-03","kind":"grant","planned":true,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":7819,"derivative":{"exercise_price":243.53,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":7819},"source":{"system":"sec-edgar","filing":"0001735276-25-000032","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000032/edgardoc.xml","form_type":"4"}},{"id":1223339,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & EVP Dev & Med Affairs"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:52.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":120,"price":242.7,"value":29124.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.46 to $242.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24542,"source":{"system":"sec-edgar","filing":"0001735276-25-000032","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000032/edgardoc.xml","form_type":"4"}},{"id":1223338,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":62341,"kind":"person","name":"Garg Pushkal","position":1,"cik":"0001829252","reported_name":"Garg Pushkal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & EVP Dev & Med Affairs"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:52.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":198,"price":241.6,"value":47836.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.21 to $242.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24662,"source":{"system":"sec-edgar","filing":"0001735276-25-000032","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000032/edgardoc.xml","form_type":"4"}}],"next_cursor":"2025-03-05T21:21:52.000000Z,1223338"}